Novo Nordisk‘s and Eli Lilly‘s blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday. Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be … Read more
As Novo Nordisk‘s sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff numbers over five years. Now sales are slowing and layoffs loom. Annual reports show that Novo’s workforce grew from around 43,260 employees in 2019 to … Read more
Wegovy popular weightloss drug now in India points Source link
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Under Jorgensen’s leadership, Novo Nordisk became a world leader in the weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments which propelled … Read more
Denmark-headquartered global healthcare major Novo Nordisk and a leading player in the diabetes market, plans to launch this oral GLP-1 drug in India by February 2022. It is billed as an oral drug that promises to not just help diabetes patients deal with the ailment but also perhaps offer other benefits such as weight reduction … Read more